软骨发育不全(ACH)赛道迎来口服药竞逐

Investment Rating - The report maintains an "Outperform" rating for the industry [8] Core Insights - The market potential for Achondroplasia (ACH) is estimated to reach $5 billion, with a focus on companies like BridgeBio, Tyra, and Huya [5] - Vosoritide, the first approved drug for ACH, has shown strong commercial performance, with sales expected to approach $1 billion in 2026 [5][22] - The report highlights the promising results of oral FGFR3 inhibitors, particularly BridgeBio's Infigratinib, which has demonstrated significant growth improvement in clinical trials [5][27] Summary by Sections 1. Market Overview - The CITIC Pharmaceutical Index fell by 0.1% during the week of March 9-13, 2026, underperforming the CSI 300 Index by 0.3 percentage points [4] - The pharmaceutical sector has seen a 0.2% increase year-to-date, lagging behind the CSI 300 Index by 0.7 percentage points [4] 2. Achondroplasia (ACH) Market Potential - ACH affects approximately 250,000 people globally, with around 45,000 cases in China, creating a significant unmet clinical need [20] - Vosoritide has shown a notable increase in annual growth rates for children with ACH, with a reported increase of 1.58 cm/year compared to placebo [21] - The success of Vosoritide validates the commercial value of the ACH market, with sales reaching $927 million in 2025 and projected to be between $975 million and $1.025 billion in 2026 [22] 3. Clinical Developments - Infigratinib, an oral FGFR3 inhibitor, has shown a 2.1 cm/year increase in growth rates in clinical trials, with plans to submit a new drug application to the FDA in the second half of 2026 [26][27] - Tyra Biosciences' FGFR3 inhibitor TYRA-300 is expected to disclose preliminary results in the second half of 2026, potentially offering better efficacy through higher dosing [36] - Huya's ABSK061 is currently in Phase II trials for children aged 3-12, with initial results anticipated in late 2026 [36] 4. Weekly Market Performance - The report notes that the pharmaceutical sector's trading volume accounted for 3.3% of the total A-share market, with a decrease of 9% compared to the previous trading period [52] - The top-performing stocks in the pharmaceutical sector included Yingke Medical (+35.2%) and Zhonghong Medical (+25.3%) during the week [53]